Published without ceasing December 22, 2015
Research that leads to improved therapies towards Alzheimer’s disease (AD) patients is single goal of Boston University School of Medicine professor of pharmacology and neurology Benjamin Wolozin, MD, PhD. He was some of six researchers awarded a sum of ~ units-year, $500,000 award in Alzheimer’s Disease Drug Discovery Research ~ means of the Edward N. & Della L. Thome Memorial Foundation.
Wolozin has been studying the pathophysiology of AD, amyotrophic lateral sclerosis and Parkinson’s infirmity (PD) for nearly 20 years and has made numerous contributions to the current field of understanding of neurodegenerative diseases. He has published greater degree of than 150 papers and book chapters without interrupti~ the topic in such high impulse journals as Science, Nature and PNAS. He in like manner holds four patents in the AD and PD fields and is the co-fall of the biotechnology company Aquinnah Pharmaceuticals, Inc.
The Edward N. & Della L. Thome Memorial Foundation was created in 2002 by the mission of advancing the freedom from disease of older adults through support of direct service projects and medical research on disease and disorders affecting them. Each year they judgment $500,000 to a faculty clause at a non-profit academic, therapeutical, non-governmental or research institution in the United States with the purpose of furthering this belonging to.
The Edward N. & Della L. Thome Memorial Foundation, Bank of America, N.A., Trustee, Awards Program in Alzheimer’s Disease Drug Discovery Research is administered ~ means of The Medical Foundation, a division of Health Resources in Action (HRiA). HRiA is a nonprofit forming in Boston that advances public freedom from disease and medical research.
Boston University Medical Center
Prednisone since a week but it seemed to call up my BG even when I ate honest protein.